Vaxcyte Inc. (PCVX): Price and Financial Metrics
PCVX Price/Volume Stats
| Current price | $116.00 | 52-week high | $119.50 |
| Prev. close | $114.13 | 52-week low | $44.20 |
| Day low | $113.58 | Volume | 883,300 |
| Day high | $117.39 | Avg. volume | 850,106 |
| 50-day MA | $85.57 | Dividend yield | N/A |
| 200-day MA | $71.76 | Market Cap | 12.62B |
PCVX Stock Price Chart Interactive Chart >
Vaxcyte Inc. (PCVX) Company Bio
Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.
Latest PCVX News From Around the Web
Below are the latest news stories about VAXCYTE INC that investors may wish to consider to help them evaluate PCVX as an investment opportunity.
Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 SharesVaxcyte Inc (NASDAQ:PCVX), a company specializing in vaccine innovation with a focus on improving global health through the development of superior vaccines, has reported an insider selling event. |
We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash WiselyWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate-- In the Study, VAX-24 Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) at all Doses Studied -- -- All 24 Serotypes of VAX-24 at Conventional 2.2 mcg PCV Dose Met or Exceeded Regulatory Immunogenicity Standards -- -- Results Confirm Potential of Carrier-Sparing, Cell-Free Platform Technology Underlying VAX-24 -- -- Topline Data from the VAX-24 Phase 3 Pivotal Non-Inferiority Study in Adults Expected in 2025 -- SAN CARLOS, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Va |
Vaxcyte Appoints Jacks Lee to Board of DirectorsSAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Jacks Lee to its Board of Directors. “We are pleased to welcome Jacks, an accomplished industry leader with extensive biopharmaceutical and vaccine manufacturing, supply and operations expertise, to Vaxcyte’s Board of Directors as we continue to reali |
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate Vaccine (PCV) Franchise -- -- Manufacturing Rights Agreement Further Strengthens Vaxcyte’s Long-Term, Global Commercial Manufacturing Strategy as Lead PCV Candidate, VAX-24, Advances into Phase 3 -- SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc |
PCVX Price Returns
| 1-mo | 47.02% |
| 3-mo | 60.55% |
| 6-mo | 67.80% |
| 1-year | 124.28% |
| 3-year | 357.41% |
| 5-year | N/A |
| YTD | 84.71% |
| 2023 | 30.97% |
| 2022 | 101.56% |
| 2021 | -10.46% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...